Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03485326 | A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | completed | — | 1,700 | AstraZenecaINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04207775 | Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy(PISCES) | completed | — | 300 | AstraZenecaINDUSTRY | 1 |
| Jul 12, 2024 |
| clinicaltrials |
| NCT04857619 | Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer | completed | — | 763 | AstraZenecaINDUSTRY | 6 | Jul 11, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT05364255 | A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03693300 | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 117 | AstraZenecaINDUSTRY | 6 | Jun 18, 2024 | clinicaltrials |
| NCT05573724 | Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 2 | Jun 18, 2024 | clinicaltrials |
| NCT02937818 | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | completed | Phase 2 | 72 | AstraZenecaINDUSTRY | 5 | Jun 7, 2024 | clinicaltrials |
| NCT02599714 | Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer(PASTOR) | completed | Phase 1 | 54 | AstraZenecaINDUSTRY | 2 | Jun 6, 2024 | clinicaltrials |
| NCT05203458 | Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients(HER2 PATH) | completed | — | 3,136 | AstraZenecaINDUSTRY | 1 | May 16, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT03433924 | An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.(POLARIS) | completed | — | 248 | AstraZenecaINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | completed | Phase 3 | 525 | AstraZenecaINDUSTRY | 4 | Mar 22, 2024 | clinicaltrials |
| NCT05239507 | OREIOS International Study(OREIOS) | completed | — | 1,127 | AstraZenecaINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT02997501 | T790M Plasma Testing Methodology Comparison and Clinical Validation(ADELOS) | completed | Phase 3 | 256 | AstraZenecaINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00516373 | A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | completed | Phase 1 | 98 | AstraZenecaINDUSTRY | 4 | Feb 22, 2024 | clinicaltrials |
| NCT03788746 | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma(PREVAIL) | completed | — | 181 | AstraZenecaINDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03643484 | IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy | completed | — | 634 | AstraZenecaINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04808050 | Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer(THASSOS-INTL) | completed | — | 748 | AstraZenecaINDUSTRY | 7 | Feb 21, 2024 | clinicaltrials |
| NCT04964908 | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia(CREEK) | completed | — | 1,088 | AstraZenecaINDUSTRY | 17 | Feb 20, 2024 | clinicaltrials |
| NCT03907969 | A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. | completed | Phase 1 / Phase 2 | 30 | AstraZenecaINDUSTRY | 2 | Feb 6, 2024 | clinicaltrials |
| NCT04958226 | A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | completed | Phase 1 | 21 | AstraZenecaINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02163733 | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 38 | AstraZenecaINDUSTRY | 4 | Jan 22, 2024 | clinicaltrials |
| NCT00494234 | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer(ICEBERG 1) | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 8 | Jan 19, 2024 | clinicaltrials |
| NCT04836975 | Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:(REVEAL) | completed | — | 45 | AstraZenecaINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT00782574 | Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients | completed | Phase 1 | 57 | AstraZenecaINDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT05395117 | A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02503436 | C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population(C-PATROL) | completed | — | 276 | AstraZenecaINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02923947 | Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 3 | Nov 27, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | completed | Phase 3 | 387 | AstraZenecaINDUSTRY | 20 | Oct 6, 2023 | clinicaltrials |
| NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 95 | AstraZenecaINDUSTRY | 3 | Oct 3, 2023 | clinicaltrials |
| NCT04667312 | Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom(CODAK) | completed | — | 115 | AstraZenecaINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY | 12 | Sep 13, 2023 | clinicaltrials |
| NCT04801186 | Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer(REMPRO) | completed | — | 1,920 | AstraZenecaINDUSTRY | 8 | Sep 7, 2023 | clinicaltrials |
| NCT05933044 | RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada(RELEVANCE) | completed | — | 662 | AstraZenecaINDUSTRY | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04590248 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma(ADAGIO) | completed | Phase 2 | 109 | AstraZenecaINDUSTRY | 5 | Aug 14, 2023 | clinicaltrials |
| NCT04742192 | Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer(EARLY-EGFR) | completed | — | 601 | AstraZenecaINDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT05825365 | Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study(PROTECT) | withdrawn | Phase 2 | 0 | AstraZenecaINDUSTRY | 0 | Aug 14, 2023 | clinicaltrials |
| NCT04495179 | A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.(AARDVARC) | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 5 | Aug 9, 2023 | clinicaltrials |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | terminated | Phase 1 | 9 | AstraZenecaINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT01063517 | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | completed | Phase 2 | 124 | AstraZenecaINDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials